The design, synthesis and structure-activity relationships of transition-state inhibitors containing the dihydroxyethylene isostere at the scissile site are described. The compounds with (2S, 3R, 4S)-4-amino-5-cyclohexyl-1-morpholino-2, 3-pentanediol at the P1-P1' site are potent renin inhibitors. (2S, 3R, 4S)-4-[N-[(2S)-3-Ethylsulfonyl-2-(1-naphthylmethyl)propionyl]-L-norleucyl]amino-5-cyclohexyl-1-morpholino-2, 3-pentanediol (2) (BW-175), which is the most potent inhibitor (IC50 : 3.3 nM against human renin) in this series, poorly inhibits cathepsin D (IC50 : 26000 nM) and pepsin (IC50 : >100000 nM), and thus it is specific for renin. Compound 2 contains only one amino acid and showed an oral bioavailability of 2.8% at 10 mg/kg and 9.7% at 30 mg/kg in rats. The interaction between renin and inhibitor 2 is discussed on the basis of molecular modeling studies.
描述了在易裂位点含有二羟基
乙烯等排体的过渡态
抑制剂的设计、合成和构效关系。在 P1-P1' 位点具有 (2S, 3R, 4S)-4-
氨基-5-环己基-1-吗啉代-2, 3-
戊二醇的化合物是有效的肾素
抑制剂。 (2S, 3R, 4S)-4-[N-[(2S)-3-乙基磺酰基-2-(1-
萘甲基)丙酰基]-L-正亮
氨酰基]
氨基-5-环己基-1-吗啉代-2, 3-
戊二醇 (2) (BW-175) 是该系列中最有效的
抑制剂(针对人肾素的 IC50:3.3 nM),对组织
蛋白酶 D(IC50:26000 nM)和胃
蛋白酶(IC50:>100000 nM)的抑制效果很差,并且因此它是针对肾素的。化合物 2 仅含有一种
氨基酸,在大鼠中显示 10 mg/kg 剂量下的口服
生物利用度为 2.8%,30 mg/kg 剂量下的口服
生物利用度为 9.7%。在分子模型研究的基础上讨论了肾素和
抑制剂 2 之间的相互作用。